All articles by vemula pravalika
vemula pravalika
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus).
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).
Cytovale’s FDA-Cleared Sepsis Diagnostic Triages First 5,000 Patients, Paves Way to New Hospital Protocols for Sepsis Management
First hospital to implement Cytovale’s IntelliSep® sepsis diagnostic tool realizes significant clinical and financial returns in first nine months of screening
Echo Hospice Receives Prestigious Center of Excellence Award from The Wound Pros
Leader in compassionate care honored for excellence in wound healing and dedication to community
Healcisio Receives Phase II STTR Funding to Continue Critical Care AI Research
Healcisio, a leader in AI and digital healthcare, announces it has received a $1 Million STTR Phase II award from the NIAID to advance the development of its critical care decision support platform and a new AI-powered software suite for abstracting and reporting quality measures.
Noul Participates in a Malaria Project Initiated by U.S. CDC with Kenya Medical Research Institute
On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by U.S. Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. The company also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability
QIAGEN launches new QIAcuity digital PCR assays for microbial applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs), further solidifying QIAGEN’s position as a leader in microbial detection and analysis.
Nobel Laureate Professor Sir Martin Evans opens Molecular Devices’ Cardiff facility to manufacture patient-derived organoids for research and drug discovery
Molecular Devices is the world’s only company offering a service to manufacture standardized, quality-tested patient-derived organoids at a scale of many millions per batch